Skip to main content

Improvement Seen in Some Features of PCOS With Weight Loss Interventions

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 5, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Nov. 4, 2024 -- Weight loss interventions are associated with improvement in some features of polycystic ovary syndrome (PCOS), according to a study published online Nov. 5 in the Annals of Internal Medicine.

Jadine Scragg, Ph.D., from the University of Oxford in the United Kingdom, and colleagues quantified the effect of weight loss interventions on clinical features of PCOS compared with usual care based on a review of randomized controlled trials. Twenty-nine comparisons with 1,529 participants were included in the primary analyses: 13, 12, and four comparisons were judged as high, some, or low risk for bias, respectively.

The researchers found that 12, nine, and eight of the comparisons used behavioral interventions, glucagon-like peptide-1 receptor agonists, and other weight loss medications, respectively. Significantly greater improvements in Homeostasis Model Assessment for Insulin Resistance, free androgen index, and menstrual frequency were seen in association with weight loss interventions (mean difference, −0.45, −2.03, and 2.64, respectively). No evidence was seen for weight loss interventions being associated with clinically or statistically significant improvements in hirsutism, quality of life, or other sex hormones.

"Clinicians may use these findings to counsel women with PCOS on the expected improvements in PCOS markers after weight loss and direct patients toward interventions, though our findings may not extend to all weight loss interventions especially if they target specific metabolic pathways," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted November 2024

Read this next

Metformin Beneficial for Osteoarthritis Knee Pain in Overweight, Obesity

THURSDAY, May 1, 2025 -- For patients with overweight or obesity and symptomatic knee osteoarthritis, metformin is associated with a greater improvement in knee pain than placebo...

Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists

WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...

Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk

MONDAY, April 21, 2025 -- Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.